What is Zacks Research’s Estimate for CPRX Q1 Earnings?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a report released on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.49 for the quarter, up from their previous forecast of $0.44. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.53 EPS, Q1 2026 earnings at $0.57 EPS, Q2 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.57 EPS.

Other equities analysts have also issued reports about the company. Stephens reiterated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $32.50.

Catalyst Pharmaceuticals Trading Up 4.6 %

Shares of Catalyst Pharmaceuticals stock opened at $24.23 on Friday. The firm has a market capitalization of $2.94 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The business’s 50-day moving average price is $22.39 and its 200-day moving average price is $21.61. Catalyst Pharmaceuticals has a 12 month low of $14.47 and a 12 month high of $24.64.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Park Square Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $29,000. Farther Finance Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $65,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.